EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

A nationwide multicenter study of the cost effectiveness of five leading drugs for pharmacological management of cervicobrachial symptoms

Norimitsu Wakao, Takeo Furuya, Toshitaka Yoshii, Hideyuki Arima, Yu Yamato, Hiroaki Nakashima, Shiro Imagama, Yasuaki Imajo, Hiroshi Miyamoto, Gen Inoue, Masayuki Miyagi, Shunsuke Kanbara und 22 weitere

Journal of Orthopaedic Science · 2025

DOI: 10.1016/j.jos.2023.12.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Orthopaedic Science, 2025. Verfasst von Norimitsu Wakao und 33 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Orthopaedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan. Electronic address: nwakao2009@yahoo.co.jp. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cervicobrachial pain frequently affects the quality of life (QOL) of the general public and has a significant economic impact on the health care systems of various countries. There are a number of treatment options for this disease, including widely-used drug therapy, but the effectiveness of each option is indeterminate, and there have been no published cost-effectiveness analysis studies so far. This prospective observational study aimed to examine the cost-effectiveness of drug treatment for cervicobrachial symptoms. METHODS: A 6-month medication regimen for each of five frequently-prescribed drugs for cervicobrachial symptoms was administered to 322 patients at 24 centers in Japan. Outcome measures, including of the EuroQol Group 5D, Short Form-8, and Visual Analog Scale (VAS), were investigated at baseline and every month thereafter. Incremental cost-effectiveness ratios (ICERs) of the drug cost to quality-adjusted life years (QALYs) were calculated. A stratified analysis of patient characteristics was also performed to identify baseline factors potentially affecting cost-effectiveness. RESULTS: The ICER of entire drug treatment for cervicobrachial symptoms was 7,491,640 yen. Compared with the reference willingness-to-pay, the ICER was assumed to not be cost-effective. A certain number of QALYs were gained during the first 3 months after the treatment intervention, but almost no QALYs were gained during the following 3 months. Stratified analysis showed that cost-effectiveness was extremely low for patients with high baseline VAS and high QOL. CONCLUSIONS: The available medications for cervicobrachial symptoms did not have excellent cost-effectiveness. Although a certain number of QALYs were gained during the first 3 months after medication, no QALYs were gained in the latter half of the study period, suggesting that it is not advisable to continue the medication needlessly. LEVEL OF EVIDENCE: II, prospective cohort study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HumansCost-Benefit AnalysisProspective StudiesFemaleMaleMiddle AgedJapanAgedQuality-Adjusted Life YearsAdultQuality of LifePain MeasurementCost-Effectiveness Analysis

Stichwörter der Autor:innen

Cervicobrachial symptomsCost effectivenessDrugsICERQALYQOL

Autor:innen und Institutionen

  • Departments of Orthopaedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan. Electronic address: nwakao2009@yahoo.co.jp.
  • Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan. Electronic address: furuya-takeo@chiba-u.jp.
  • Section of Orthopaedic Surgery; and Spinal Surgery, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Electronic address: yoshii.orth@tmd.ac.jp.
  • Department of Orthopaedic Surgery, Hamamatsu University, School of Medicine, Hamamatsu, Japan. Electronic address: arihidee@yahoo.co.jp.
  • Department of Orthopaedic Surgery, Hamamatsu University, School of Medicine, Hamamatsu, Japan. Electronic address: yamato@hama-med.ac.jp.
  • Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: hirospine@med.nagoya-u.ac.jp.

Zitieren

APA

Wakao, N., Furuya, T., Yoshii, T., Arima, H., Yamato, Y., Nakashima, H., Imagama, S., Imajo, Y., Miyamoto, H., Inoue, G., Miyagi, M., Kanbara, S., Iizuka, Y., Chikuda, H., Watanabe, K., Kobayashi, K., Tsushima, M., Miyazaki, M., Yagi, M., …, & Project Committee of the Japanese Society for Spine Surgery and Related Research (JSSR) (2025). A nationwide multicenter study of the cost effectiveness of five leading drugs for pharmacological management of cervicobrachial symptoms. Journal of Orthopaedic Science. https://doi.org/10.1016/j.jos.2023.12.004

Vancouver

Wakao N, Furuya T, Yoshii T, Arima H, Yamato Y, Nakashima H, et al. A nationwide multicenter study of the cost effectiveness of five leading drugs for pharmacological management of cervicobrachial symptoms. Journal of Orthopaedic Science. 2025. doi:10.1016/j.jos.2023.12.004

BibTeX
@article{Wakao2025,
  author = {Wakao, Norimitsu and Furuya, Takeo and Yoshii, Toshitaka and Arima, Hideyuki and Yamato, Yu and Nakashima, Hiroaki and Imagama, Shiro and Imajo, Yasuaki and Miyamoto, Hiroshi and Inoue, Gen and Miyagi, Masayuki and Kanbara, Shunsuke and Iizuka, Yoichi and Chikuda, Hirotaka and Watanabe, Kei and Kobayashi, Kazuyoshi and Tsushima, Mikito and Miyazaki, Masashi and Yagi, Mitsuru and Suzuki, Satoshi and Takahata, Masahiko and Hongo, Michio and Koda, Masao and Nagata, Keiji and Mori, Kanji and Suzuki, Akinobu and Kaito, Takashi and Murotani, Kenta and Miyakoshi, Naohisa and Hashizume, Hiroshi and Matsuyama, Yukihiro and Kawakami, Mamoru and Haro, Hirotaka and Project Committee of the Japanese Society for Spine Surgery and Related Research (JSSR), Project Committee of the Japanese Society for Spine Surgery and Related Research (JSSR)},
  title = {A nationwide multicenter study of the cost effectiveness of five leading drugs for pharmacological management of cervicobrachial symptoms},
  journal = {Journal of Orthopaedic Science},
  year = {2025},
  doi = {10.1016/j.jos.2023.12.004}
}
Kostenlos starten →